Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
1. A method for delivering Adalimumab into a wall of the small intestine, the method comprising:
swallowing a drug delivery device comprising a capsule, an actuator having a first configuration and a second configuration, and a solid Adalimumab preparation operably coupled to the actuator, the solid Adalimumab preparation comprising a therapeutically effective dose of Adalimumab, the preparation being contained within the capsule in the first configuration and advanced out of the capsule and into the wall of the small intestine in the second configuration so as to insert the solid Adalimumab preparation into the wall of the small intestine wherein the solid Adalimumab preparation has a tissue penetrating shape configured for penetration of the wall of the small intestine; and
actuating the actuator responsive to a condition in the small intestine to deliver the solid Adalimumab preparation into the wall of the small intestine.
2. The method of claim 1 , wherein the condition is a selected pH.
3. The method of claim 2 , wherein the pH is above about 7.1.
4. The method of claim 1 , wherein a weight percent of Adalimumab in the preparation comprises between 8 to 12%.
5. The method of claim 1 , wherein the dose of Adalimumab in the Adalimumab preparation is in a range from 1 to 5 mg.
6. The method of claim 5 , wherein the dose of Adalimumab is in the Adalimumab preparation is in a range from 2 to 4 mg.
7. The method of claim 1 , wherein the Adalimumab preparation comprises at least one pharmaceutical excipient.
8. The method of claim 7 , wherein the at least one pharmaceutical excipient comprises at least one of a binder, a preservative or a disintegrant.
9. The method of claim 1 , further comprising retaining the Adalimumab preparation within the intestinal wall after insertion.
10. The method of claim 9 , wherein retaining comprises anchoring at least one of a barb or an inverse taper shape of the Adalimumab preparation in intestinal wall tissue.
11. The method of claim 1 , wherein delivering the Adalimumab preparation comprises applying a force to the Adalimumab preparation.
12. The method of claim 11 , wherein the Adalimumab preparation is advanced completely into the intestinal wall by such application of force.
13. The method of claim 11 , wherein the force is a mechanical force applied to a surface of Adalimumab preparation.
14. The method of claim 1 , wherein the Adalimumab preparation produces a release of Adalimumab with a t½ in a range of 6 to 24 hours.
15. The method of claim 1 , wherein the Adalimumab preparation produces a release of Adalimumab with a t½ of 40 days.
16. The method of claim 1 , further comprising:
using the dose of delivered Adalimumab to treat an autoimmune disease selected from the group consisting of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
17. The method of claim 16 , where the autoimmune disease is rheumatoid arthritis.
18. The method of claim 16 , where the autoimmune disease is psoriatic arthritis.
19. The method of claim 16 , where the autoimmune disease is ankylosing spondylitis.
20. The method of claim 16 , where the autoimmune disease is juvenile idiopathic arthritis.